Please assess the completion status of the following clinical trial:

Trial Title: BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥18 years, able and willing to provide written informed consent and to comply with the study protocol.~* Laboratory parameters as specified below:~  * Hematologic: Platelet count \>40x10\^9/liter (L) (may be post-transfusion); absolute neutrophil count \>1.0x10\^9/L (growth factor use is allowed to bring pre-treatment neutrophils to \>1.0x10\^9 cells/L if marrow infiltration is involved).~ * Hepatic: Total bilirubin \<3 x upper limit normal (ULN); and aspartate aminotransferase and alanine transaminase ≤3 x ULN.~ * Renal: Creatinine clearance ≥50 milliliters/minute (as estimated by the Cockcroft Gault equation or as measured by nuclear medicine scan or 24-hour urine collection); participants requiring hemodialysis will be excluded.~* Anticipated survival of at least 6 months.~* Eastern Cooperative Oncology Group performance status of 0 to 2.~* Female participants of childbearing potential and non-sterile males must have agreed to practice at least one of the following methods of birth control with partner(s) throughout the study and for ≥3 months after discontinuing zanubrutinib or ≥18 months following obinutuzumab treatment, whichever was longer: total abstinence from sexual intercourse, double barrier contraception, intra uterine device or hormonal contraceptive initiated at least 3 months prior to first administration of study drug.~* Male participants must have not donated sperm from first study drug administration, until 3 months after zanubrutinib discontinuation or 18 months following obinutuzumab treatment, whichever is longer.~Exclusion Criteria:~* Known central nervous system lymphoma or leukemia.~* Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.~* Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.~* History of significant cardiovascular disease.~* Severe or debilitating pulmonary disease.~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy.~* Prior Bruton tyrosine kinase inhibitor treatment.~* Used medications which were strong cytochrome P450 (CYP) 3A inhibitors and strong CYP3A inducers.~* Vaccination with a live vaccine within 28 days of the initiation of treatment.~* Allogeneic stem cell transplantation within 6 months, or had active graft versus host disease requiring ongoing immunosuppression.~* Receipt of the following treatment prior to first administration of zanubrutinib, corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 3 weeks, monoclonal antibody within 4 weeks.~* Participated in any investigational drug study within 28 days of study entry, or not recovered from non-hematologic toxicity of any prior chemotherapy up to ≤ Grade 1 (except for alopecia).~* History of other active malignancies within 2 years of study entry.~* Major surgery in the past 4 weeks.~* Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with human immunodeficiency virus, human T cell lymphotropic virus seropositive status.~* Inability to comply with the study procedures.~* Pregnant or nursing women.~* Any illness or condition that in the opinion of the investigator may have affected the safety of treatment or evaluation of any study's endpoints.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zanubrutinib and Obinutuzumab (Type: EXPERIMENTAL): In the dose-escalation part, dose levels and regimens were evaluated. In the indication-specific expansion cohorts, participants were assigned to different cohorts based on histology type.

Based on this trial design, predict the completion outcome and termination type (if applicable).